Industries > Pharma > Global Inhalation Anaesthesia Market Report 2019-2029
Global Inhalation Anaesthesia Market Report 2019-2029
Analysis by Product Type (Sevoflurane, Desflurane, Isoflurane), Application (Induction, Maintenance), Plus Company and Country Analysis and Forecasts
Market Definition:
• Inhalational anesthesia (IA) become the anesthetic of choice over Intravenous Anesthesia (IVA) among majority of healthcare practitioners, as it helps avoid excessive dosage and keeps the patient’s autonomic functions intact. IA has lower risk of delirium and is cost effective compared to IVA
• Inhalational anesthesia used for sedation as well as for the induction and maintenance of general anesthesia. The most common inhalational anesthetics are sevoflurane, desflurane, and nitrous oxide.
Market Overview and Trends
• To address the environmental impact of anesthetic gases, new technologies are being developed to scavenge them from hospital vents and recycle them.
• These anesthetic gases contribute up to 1.0% of global carbon dioxide emissions, leading to greater environmental damage.
• The major concern in using anesthetic gases is that patient use accounts for only 5.0% and the rest 95.0% is released into the atmosphere which contributes to global warming
Market Dynamics:
Factors Influencing the Market Growth:
• Rapid rise in aging population suffering from cancer, cardiovascular, spinal, orthopedic, respiratory, gastrointestinal, neurological, and other diseases and disorders is anticipated to drive the growth
• Increasing number of emergency cases and accidents are also expected to positively influence market growth
• Increasing number of orthopedic procedures such as ligament and other soft tissue repair procedures is also contributing to growth of the day care ambulatory surgeries, which is expected to boost usage of inhalation anesthesia.
Factors Restraining the Market Growth:
• Inhalational anesthetics cause respiratory depression, a decrease in arterial blood pressure and cerebral metabolic demand, and an increase in cerebral blood flow that may hinder the growth of the market.
Market Segmentation 2019-2029:
The inhalation anesthesia market is segmented on the product type, application, and geography.
Product Type
• Sevoflurane Market, 2019-2029
• Desflurane Market, 2019-2029
• Isoflurane Market, 2019-2029
Application
• Induction Market, 2019-2029
• Maintenance Market, 2019-2029
Geographic Breakdown
Focused regional forecasts and analysis explore the future opportunities:
• North America Market, 2019-2029
• Europe Market, 2019-2029
• Asia-Pacific Market, 2019-2029
• LAMEA Market, 2019-2029
Competitive Analysis:
• Research and development is the primary strategy adopted by the key players in the inhalation anesthesia market.
• These companies have developed various strategies and developments such as product launch, partnerships, mergers & acquisitions, joint venture, and collaborations.
• Baxter Healthcare is the only player with all the 3 products in its portfolio. AbbVie Inc. has sevoflurane and isoflurane in its portfolio. Piramal Healthcare presently has sevoflurane and isoflurane in its portfolio and may capture a significant market share of Baxter in the years to come owing to new product launches
Major Market Players:
Halocarbon Products Corporation; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Download sample pages
Complete the form below to download your free sample pages for Global Inhalation Anaesthesia Market Report 2019-2029Download sample pages
Complete the form below to download your free sample pages for Global Inhalation Anaesthesia Market Report 2019-2029
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market
05 October 2021
